Study on biomarkers for the effect and safety of the treatment with Atezolizumab + Bevacizumab for liver cancer
- Conditions
- unresectable advanced hepatocellular carcinoma
- Registration Number
- JPRN-UMIN000047758
- Lead Sponsor
- agoya University Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 99
Not provided
Patients who wish to be excluded from the study. Patients who are pregnant, or lactating, may become pregnant, intend to become pregnant, or who wish to have a baby. Patients with the following serious complications: 1. Cardiovascular abnormalities such as heart failure, angina pectoris, or arrhythmia are difficult to control even after treatment. 2. Myocardial infarction within 6 months of onset 3. Renal failure 4. Active infectious disease except for viral hepatitis 5. Active gastrointestinal bleeding 6. Other active cancer requiring treatment 7. Hepatic encephalopathy or severe mental disorder 8. Severe drug allergy 9. Serious autoimmune disease. Other conditions that the physician deems inappropriate for the safe conduct of this study.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method